Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 446-453

  Fust, Kelly ^a   Li, Xiaoyan ^b   Maschio, Michael ^a   Barron, Richard ^b   Weinstein, Milton C ^a,c   Parthan, Anju ^a   Walli Attaei, Marjan ^a,e   Chandler, David B ^b   Lyman, Gary H ^d,f  

^a OPTUM   (United States)

^b AMGEN INC   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f USA   (United States)

Author keywords

Cost effectiveness; Febrile neutropenia; Filgrastim; Ovarian cancer; Pegfilgrastim; Prophylaxis

Indexed keywords

DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PEER REVIEW; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS;

COST EFFECTIVENESS; FEBRILE NEUTROPENIA; FILGRASTIM; OVARIAN CANCER; PEGFILGRASTIM; PROPHYLAXIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; TAXOIDS; TOPOTECAN;

EID: 84901679224     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.014     Document Type: Article

References (40)

1. B. Dulisse, X. Li, J.A. Gayle, R.L. Barron, F.R. Ernst, and K.J. Rothman et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia J Med Econ 2013 10.3111/13696998.2013.782034
2. R.K. Hanna, M.S. Poniewierski, R.A. Laskey, M.A. Lopez, A. Shafer, and L. Van Le et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer Gynecol Oncol 129 1 2013 74 80 10.1016/j.ygyno.2012. 12.017
3. H. Wildiers, and M. Reiser Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Crit Rev Oncol Hematol 77 3 2011 221 240 10.1016/j.critrevonc.2010.02. 002
4. J.M. Fauci, J.M. Whitworth, K.E. Schneider, A. Subramaniam, B. Zhang, and P.J. Frederick et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer Gynecol Oncol 122 3 2011 532 535 10.1016/j.ygyno.2011.05.023
5. J. Crawford, H. Ozer, R. Stoller, D. Johnson, G. Lyman, and I. Tabbara et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 3 1991 164 170 10.1056/NEJM199107183250305
6. C.L. Vogel, M.Z. Wojtukiewicz, R.R. Carroll, S.A. Tjulandin, L.J. Barajas-Figueroa, and B.L. Wiens et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 6 2005 1178 1184 10.1200/JCO.2005.09.102
7. NEUPOGEN® (Filgrastim) prescribing information Amgen 2013
8. M.D. Green, H. Koelbl, J. Baselga, A. Galid, V. Guillem, and P. Gascon et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 1 2003 29 35
9. F.A. Holmes, J.A. O'Shaughnessy, S. Vukelja, S.E. Jones, J. Shogan, and M. Savin et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 3 2002 727 731
10. D. Weycker, J. Hackett, J.S. Edelsberg, G. Oster, and A.G. Glass Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 3 2006 402 407 10.1345/aph.1G516
11. Neulasta® (pegfilgrastim) prescribing information Amgen 2010
12. NCCN Guidelines Myeloid, growth factors v1 2013
13. T.J. Smith, J. Khatcheressian, G.H. Lyman, H. Ozer, J.O. Armitage, and L. Balducci et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 19 2006 3187 3205 10.1200/JCO.2006.06.4451
14. T.M. Numnum, K.J. Kimball, R.P. Rocconi, L.C. Kilgore, and J.M. Straughn Jr. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma - a cost-effectiveness analysis Int J Gynecol Cancer 17 5 2007 1019 1024 10.1111/j.1525-1438.2007.00915.x
15. N.C.C.N. Guidelines Ovarian Cancer v2 2013
16. P.G. Rose, J.A. Blessing, H.G. Ball, J. Hoffman, D. Warshal, and K. DeGeest et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2 2003 130 135
17. E.M. Swisher, D.G. Mutch, J.S. Rader, A. Elbendary, and T.J. Herzog Topotecan in platinum- and paclitaxel-resistant ovarian cancer Gynecol Oncol 66 3 1997 480 486 10.1006/gyno.1997.4787
18. C.F. Verschraegen, T. Sittisomwong, A.P. Kudelka, E. Guedes, M. Steger, and T. Nelson-Taylor et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J Clin Oncol 18 14 2000 2733 2739
19. G. von Minckwitz, S. Kummel, A. du Bois, W. Eiermann, H. Eidtmann, and B. Gerber et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study Ann Oncol 19 2 2008 292 298 10.1093/annonc/mdm438
20. S. Whyte, K.L. Cooper, M.D. Stevenson, J. Madan, and R. Akehurst Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom Value Health 14 4 2011 465 474 10.1016/j.jval.2010.10.037
21. E. Arias United States life tables, 2007 Natl Vital Stat Rep 59 2011 1 60
22. D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, and G. Lyman Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer Chemotherapy 58 1 2012 8 18 10.1159/000335604
23. G.H. Lyman, A. Lalla, R.L. Barron, and R.W. Dubois Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States Clin Ther 31 5 2009 1092 1104 10.1016/j.clinthera.2009.05.003
24. L.J. Havrilesky, G. Broadwater, D.M. Davis, K.C. Nolte, J.C. Barnett, and E.R. Myers et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment Gynecol Oncol 113 2 2009 216 220 10.1016/j.ygyno.2008.12.026
25. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
26. R.E. Brown, and J. Hutton Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anticancer Drugs 9 10 1998 899 907
27. N. Lathia, P.K. Isogai, C. De Angelis, T.J. Smith, M. Cheung, and N. Mittmann et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients J Natl Cancer Inst 105 15 2013 1078 1085 10.1093/jnci/djt182
28. J. Crawford, D.C. Dale, N.M. Kuderer, E. Culakova, M.S. Poniewierski, and D. Wolff et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Canc Netw 6 2 2008 109 118
29. M. Shayne, J. Crawford, D.C. Dale, E. Culakova, and G.H. Lyman Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 100 3 2006 255 262 10.1007/s10549-006-9254-4
30. S.D. Grosse Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Expert Rev Pharmacoecon Outcomes Res 8 2 2008 165 178 10.1586/14737167.8.2.165
31. D.M. Cutler, A.B. Rosen, and S. Vijan The value of medical spending in the United States, 1960-2000 N Engl J Med 355 9 2006 920 927 10.1056/NEJMsa054744
32. C.R. Flowers, J. Seidenfeld, E.J. Bow, C. Karten, C. Gleason, and D.K. Hawley et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 31 6 2013 794 810 10.1200/JCO.2012.45.8661
33. L. Repetto, M. Pace, S. Mammoliti, M. Bruzzone, S. Chiara, and C. Oliva et al. The impact of received dose intensity on the outcome of advanced ovarian cancer Eur J Cancer 29A 2 1993 181 184
34. G. Hill, R. Barron, K. Fust, M.E. Skornicki, D.C. Taylor, and M.C. Weinstein et al. Primary versus secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses J Med Econ 2013 10.3111/13696998.2013.844160
35. A. Eldar-Lissai, L.E. Cosler, E. Culakova, and G.H. Lyman Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy Value Health 11 2 2008 172 179 10.1111/j.1524-4733.2007.00242.x
36. G. Lyman, A. Lalla, R. Barron, and R.W. Dubois Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States Curr Med Res Opin 25 2 2009 401 411 10.1185/03007990802636817
37. S.D. Ramsey, Z. Liu, R. Boer, S.D. Sullivan, J. Malin, and Q.V. Doan et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy Value Health 12 2 2009 217 225 10.1111/j.1524-4733.2008.00434.x
38. E.A. Calhoun, C.H. Chang, E.E. Welshman, D.A. Fishman, J.R. Lurain, and C.L. Bennett Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients Oncologist 6 5 2001 441 445
39. B.V. Fortner, T.A. Okon, L. Zhu, K. Tauer, K. Moore, and D. Templeton et al. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice Community Oncol 1 2004 23 28
40. B.V. Fortner, K. Tauer, L. Zhu, T.A. Okon, K. Moore, and D. Templeton et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities BMC Cancer 4 2004 22 10.1186/1471-2407-4-22